Beacon Therapeutics News and Activities

Beacon Therapeutics is owned by Syncona.

Syncona is one of the...

• FTSE 350;
• TOB Iconic 10,000.

Syncona is a company listed under the stock ticker SYNC (GB).

Syncona has a direct presence in 3 countries.

Syncona has 11 subsidiaries including Anaveon, Autolus Therapeutics and Beacon Therapeutics.

They are in:

• Biotechnology83%
• Holding8%
• Other8%

Acquisition, funding and merger involving Syncona.

• Beacon Therapeutics has just announced a $75 Million fundraising (posted on January 8 2026).
• Beacon Therapeutics has just announced a $170 Million fundraising (posted on July 8 2024).

View the org chart displaying its 17 main executives

Most searched biographies at Beacon Therapeutics

• Lance Baldo, Chief Executive Officer
• Dave Fellow, Non-Executive Chairman of the Board
• Dmitrij Hristodorov, Investor Director

Popular executive movements at Beacon Therapeutics

• Ryan Robinson has joined the company as Chief Financial Officer  (posted on March 13 2026).

Create your alert
to follow the executive moves at Beacon Therapeutics.

Syncona has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Beacon Therapeutics

• Beacon Therapeutics Announces Positive 3-Month Data from Phase 2 DAWN Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa (XLRP) - Beacon Therapeutics
• Beacon Therapeutics Announces Positive 24-Month Data from Phase 2 SKYLINE Trial of AGTC-501 in Patients with X-Linked Retinitis Pigmentosa - Beacon Therapeutics
• Beacon Therapeutics Presents 36-Month Interim Results from Phase I/2 HORIZON Trial of AGTC-501 in Patients with XLRP - Beacon Therapeutics
• Subretinal Gene Therapy Drug AGTC-501 for XLinked Retinitis Pigmentosa (XLRP) Phase 1/2 Multicenter Study (HORIZON): 36-Month Interim Results - Beacon Therapeutics
• Beacon Therapeutics Appoints Lance Baldo, MD as Chief Executive Officer and Thomas Biancardi as Chief Financial Officer - Beacon Therapeutics
• Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications - Beacon Therapeutics
• Beacon Therapeutics Treats First Patient in VISTA Registrational Trial for AGTC-501 - Beacon Therapeutics
• Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies - Beacon Therapeutics
• Ascend acquires GMP manufacturing capacity in Alachua, Florida; Enters long-term partnership with Beacon Therapeutics for clinical and commercial AAV production - Beacon Therapeutics
• Subretinal AGTC-501 Gene Therapy for XLRP: 12-Month Interim Safety & Efficacy Results of the Phase 2 SKYLINE Trial - Beacon Therapeutics
• View more press releases Close

Social media about Beacon Therapeutics

• Beacon Therapeutics on Wikipedia, Google News & Yahoo Finance
• Beacon Therapeutics on LinkedIn, X (Twitter) & YouTube